Delphi Diagnostics Inc. reported new data at the 2025 San Antonio Breast Cancer Symposium showing that its Endocrine Activity Index assay may identify postmenopausal patients with hormone receptor positive, HER2-negative breast cancer who derive meaningful benefit from extended endocrine therapy beyond five years, based on a retrospective analysis of the NRG Oncology NSABP B-42 trial evaluating extended letrozole treatment.

Why extended endocrine therapy remains one of the most clinically unresolved decisions in hormone receptor positive breast cancer care

Extended endocrine therapy has occupied an uncomfortable middle ground in breast cancer management for more than a decade. While multiple trials have shown statistically significant reductions in late recurrence, the absolute benefit has remained modest at a population level, often in the low single-digit percentage range. This has left clinicians balancing marginal recurrence reduction against cumulative toxicity, adherence fatigue, and long-term quality-of-life concerns in postmenopausal patients.

The lack of a reliable predictive tool has meant that extended therapy decisions are frequently driven by clinicopathologic risk rather than true endocrine sensitivity. Node status, tumor size, and grade provide risk context but do not directly measure whether a tumor remains biologically dependent on estrogen signaling after five years of suppression. As a result, many patients are exposed to prolonged therapy with limited likelihood of benefit, while others who might benefit more substantially are not clearly identifiable.

What the NSABP B-42 experience reveals about the limits of population-level benefit without predictive stratification

The NSABP B-42 trial is emblematic of the broader challenge. The study demonstrated a statistically significant improvement in breast cancer-free interval with extended letrozole therapy, but the absolute benefit of approximately three percentage points at ten years limited its impact on clinical practice. Guidelines acknowledged the option, but adoption remained inconsistent, particularly in lower-risk subgroups.

From an industry and regulatory perspective, B-42 reinforced a recurring theme in endocrine therapy trials. Population averages obscure meaningful heterogeneity. Some patients derive substantial benefit, while others experience toxicity without measurable gain. Without a way to separate these groups prospectively, extended therapy has remained a discretionary rather than standard intervention.

How endocrine pathway activity differs from recurrence risk and why that distinction matters for late therapy decisions

The Endocrine Activity Index enters this debate by focusing on a different biological question. Rather than estimating recurrence risk based on proliferation or composite gene expression patterns, the assay measures activity within the estrogen and progesterone signaling pathways themselves. This distinction is not semantic. Recurrence risk reflects probability, while endocrine activity reflects mechanism.

Industry observers note that late recurrences in hormone receptor positive breast cancer are often driven by residual endocrine-responsive disease rather than aggressive, proliferation-driven biology. A test aligned with pathway dependence is therefore conceptually better suited to predict benefit from continued endocrine suppression than tools optimized for early recurrence or chemotherapy selection.

Why the magnitude of benefit observed in high endocrine activity patients shifts the clinical conversation

The most consequential aspect of the reported analysis is not the statistical significance but the size of the observed benefit in selected patients. Patients with high endocrine activity scores experienced absolute reductions in breast cancer-free interval events that reached seven to ten percentage points at ten years, particularly in node-positive disease.

If reproducible, this level of benefit crosses a threshold that materially alters shared decision-making. Clinicians are far more likely to recommend extended therapy when the expected gain is clearly clinically meaningful rather than marginal. Conversely, the absence of benefit in low endocrine activity patients supports treatment de-escalation without compromising outcomes.

What this analysis suggests about heterogeneity within node-positive and node-negative hormone receptor positive disease

Node-positive status has long been used as a blunt proxy for recurrence risk and extended therapy consideration. However, the data suggest that nodal involvement alone is insufficient to define endocrine benefit. High endocrine activity appears to identify a subset of node-positive patients who experience disproportionate benefit from prolonged therapy, while others do not.

This nuance matters because node-positive patients are often defaulted into longer therapy durations despite wide biological variability. A mechanism-focused assay could allow clinicians to differentiate between patients for whom extended therapy is biologically rational and those for whom it represents overtreatment.

Regulatory and evidentiary limitations that still constrain clinical adoption of the Endocrine Activity Index

Despite the strength of the signal, regulatory and guideline implications remain constrained by the retrospective nature of the analysis. The NSABP B-42 dataset is robust and derived from a randomized trial, but the predictive hypothesis was not pre-specified. From a regulatory standpoint, this places the findings in an exploratory category.

Prospective validation will be critical, ideally within trials explicitly designed to test biomarker-guided extended therapy strategies. Without such data, broad guideline endorsement is unlikely, regardless of biological plausibility.

Commercial and reimbursement questions that will shape whether this assay moves beyond academic interest

From a commercial perspective, extended endocrine therapy represents a sizable but cautious market. Payers have historically resisted reimbursing additional genomic tests unless they demonstrably reduce downstream costs or prevent unnecessary treatment. The Endocrine Activity Index will need to show that it meaningfully reduces prolonged therapy in low-benefit patients rather than simply shifting cost from drugs to diagnostics.

Workflow integration will also matter. Oncologists already contend with multiple genomic reports, and adoption will depend on whether the assay delivers clear, binary guidance rather than incremental nuance that complicates decision-making.

What clinicians and industry observers are likely to scrutinise as Delphi Diagnostics advances this assay

Several questions remain unresolved. It is unclear how the assay performs across different endocrine therapy sequences, adherence patterns, and real-world treatment durations. The interaction between endocrine activity and other biological factors, including tumor microenvironment and genomic instability, remains unexplored.

Transparency around conflicts of interest and independent validation will also be closely watched as the assay moves toward broader clinical exposure. The breast cancer diagnostics field has seen both transformative tools and cautionary tales, making skepticism a default posture.

Why this data reflects a broader shift toward mechanism-aligned diagnostics in breast cancer management

Beyond the specifics of extended endocrine therapy, the data highlight a broader industry shift toward diagnostics that align with treatment mechanism rather than outcome correlation alone. As survivorship periods lengthen and late recurrence becomes a dominant concern, static risk models may prove insufficient.

Tools that capture ongoing biological dependency rather than historical risk could play an increasing role in long-term treatment planning. Whether the Endocrine Activity Index ultimately fulfills that promise will depend on prospective evidence, payer acceptance, and clinical usability rather than retrospective signal strength alone.

  Delphi Diagnostics Inc, Endocrine Activity Index, extended endocrine therapy, HER2-negative breast cancer, HR-positive breast cancer, letrozole, SABCS 2025